Publications by authors named "Haley Altamura"

Claim this Profile
L
Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy.
Ilaria S Pagani, Naranie Shanmuganathan, Phuong Dang, Verity A Saunders, Randall Grose, Haley K Altamura

Blood· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.
Naranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, Jinghua Feng, Daniel Thomson, Haley Altamura

Haematologica· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
Naranie Shanmuganathan, Ilaria S Pagani, David M Ross, Sahee Park, Agnes S M Yong, Haley K Altamura

Blood· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.
Ilaria S Pagani, Phuong Dang, Verity A Saunders, Randall Grose, Naranie Shanmuganathan, Haley Altamura

Leukemia· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic myeloid leukaemia: The dangers of not knowing your BCR-ABL1 transcript.
Kirsty Sharplin, Haley Altamura, Kerry Taylor, Jeremy Wellwood, Debra Taylor

Leuk Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.
Susan Branford, Paul Wang, David T Yeung, Daniel Thomson, Adrian Purins, Haley Altamura

Blood· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Wendy T Parker, David T O Yeung, Alexandra L Yeoman, Haley K Altamura, Bronte A Jamison

Blood· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.
Susan Branford, David T Yeung, Wendy T Parker, Nicola D Roberts, Leanne Purins, Haley K Altamura

Blood· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
Susan Branford, David T Yeung, David M Ross, Jodi A Prime, Chani R Field, Haley K Altamura

Blood· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis